乳腺癌治疗相关的抗体偶联药物及其耐药机制研究进展  

Research progress in antibody-drug conjugates for breast cancer treatment and their drug resistance mechanisms

作　　者：潘学强 李笑 李美霞 李可 姜蕊 PAN Xueqiang;LI Xiao;LI Meixia;LI Ke;JIANG Rui(Cancer Research and Treatment Center,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250000,China)

机构地区：[1]山东省第一医科大学附属省立医院肿瘤研究治疗中心,山东济南250000

出　　处：《山东医药》2025年第2期144-148,共5页Shandong Medical Journal

摘　　要：乳腺癌已成为全球女性最常见的恶性肿瘤,随病情进展极易发生耐药。抗体偶联药物(ADC)是一种新型靶向生物制剂,通过特异性抗体与细胞毒性有效载荷的结合,精准递送靶向抗原,为乳腺癌的治疗提供了新方向。目前,ADC已逐渐用于乳腺癌的治疗中。根据靶向抗原的不同可将ADC分为靶向人表皮生长因子受体2类ADC、靶向人滋养细胞表面抗原类ADC及其他ADC。乳腺癌治疗相关ADC的耐药机制与ADC抗原表达水平下降、ADC处理过程异常和化疗有效载荷的变化有关。深入研究乳腺癌治疗相关ADC及其耐药机制,可为改善乳腺癌患者的预后提供参考。Breast cancer has become the most prevalent malignant tumor among women worldwide,with drug resis tance frequently developing as the disease progresses.Antibody-drug conjugates(ADCs),as novel targeted biologics,of fer a promising therapeutic direction for breast cancer through their unique mechanism combining specific antibodies with cytotoxic payloads to achieve precise antigen-targeted delivery.Currently,ADCs have been increasingly applied in clinical breast cancer management.Based on their target antigens,ADCs can be classified into three main categories:human epi dermal growth factor receptor 2(HER2)-targeted ADCs,human trophoblast cell-surface antigen(Trop-2)-targeted ADCs,and other types of ADCs.The resistance mechanisms associated with ADC therapy in breast cancer primarily involve de creased antigen expression levels,abnormalities in ADC processing pathways,and alterations in chemotherapeutic payload efficacy.In-depth investigations into ADC therapies and their resistance mechanisms could provide valuable insights for improving clinical outcomes in breast cancer patients.

关 键 词：抗体偶联药物 人表皮生长因子受体2 人滋养细胞表面抗原 乳腺癌 肿瘤耐药 

分 类 号：R737.9[医药卫生—肿瘤]